You are here: Industry Insights > Aldeyra Therapeutics

News List

Aldeyra plans reproxalap phase 3 after wrapping up dry eye disease trial fiercebiotech
September 28, 2018
Shares in Aldeyra rose more than 30% in premarket trading following the news.
Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Clinical Trial americanpharmaceuticalreview
September 27, 2018
Aldeyra Therapeutics announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease.
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial biospace
April 25, 2018
Aldeyra Therapeutics, Inc. today announced that it has enrolled the first patient in a Phase 3 clinical trial of topical ocular reproxalap for the treatment of allergic conjunctivitis.
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial biospace
January 31, 2018
Aldeyra Therapeutics, today announced that it has enrolled the first patient in a Phase 2b clinical trial of topical ocular reproxalap for the treatment of dry eye disease (DED).